查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2152373

重磅抗癌藥物品牌市場規模、佔有率和趨勢分析報告：按品牌、療法、分銷管道、地區和細分市場預測（2026-2033 年）

Blockbuster Oncology Brands Market Size, Share & Trends Analysis Report By Brands (Opdivo, Keytruda, Perjeta, Ibrance), By Treatment (Lung Cancer, Lymphoma), By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

預計到 2025 年，全球重磅抗癌藥物品牌的市場規模將達到 472 億美元，到 2026 年將擴大到 510 億美元，到 2033 年將達到 874 億美元，2026 年至 2033 年的複合年成長率為 8.0%。

北美市場處於領先地位，預計到 2025 年將佔銷售額的 38.0%。各年齡層各種癌症發生率的上升，以及癌症研究的不斷進步，正在推動市場成長。

此外，免疫療法、標靶治療和細胞療法等創新療法的日益普及，為患者提供了更廣泛的治療選擇，這進一步促進了市場成長。

重磅藥物指的是那些備受追捧、年銷售額超過10億美元的藥品，這些藥品能為製藥公司帶來豐厚的利潤。全球監管機構正在加快新療法作為第一線治療方案的核准速度。此外，各公司也一直在大力投資新藥製劑的研發。這些因素共同推動了全球重磅抗癌藥物品牌市場的快速成長。

根據美國癌症協會（ACS）發布的《癌症統計》報告，預計到2026年1月，美國將新增約210萬例癌症病例，並有60萬人死於癌症。國際癌症研究機構（IARC）報告稱，男性最常見的癌症類型是肺癌和前列腺癌，女性最常見的癌症類型是乳癌。鑑於患者數量龐大且持續成長，製藥公司正在加速研發創新抗癌藥物。雖然這些新療法對患者來說價格昂貴，但有利的保險報銷政策促進了重磅抗癌​​藥物的商業性成功，並推動了整體市場成長。

包括美國食品藥物管理局（FDA）、歐洲藥品管理局（EMA）和英國藥品和保健產品監管局（MHRA）在內的全球監管機構正在加快癌症治療創新藥物療法的核准流程，例如標靶免疫療法、CAR-T細胞療法和單株抗體。腫瘤學家基於腫瘤基因和分子譜分析而採用的個人化治療方案，進一步提高了治療效果，並推動了市場需求。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章：重磅抗癌藥物品牌市場：變數、趨勢與範圍

  • 市場概況及未來展望
  • 市場規模和成長前景
  • 市場動態
  • 重磅抗癌藥物品牌市場分析工具

第4章：重磅抗癌藥物品牌市場：品牌特定估算與趨勢分析

  • 重磅腫瘤品牌市場：2025 年和 2033 年品牌特定波動分析
  • 奧普迪沃
  • Keytruda
  • Perjeta
  • Ibrance
  • TECENTRIQ
  • 加吉巴
  • 塔格里索
  • 達爾扎雷克斯
  • 澤朱拉
  • 來那度胺
  • Imbruvica
  • 其他

第5章：重磅抗癌藥物品牌市場：依療法分類的估算與趨勢分析

  • 重磅抗癌藥物品牌市場：按療法分類的趨勢分析（2025 年和 2033 年）
  • 肺癌
  • 乳癌
  • 多發性骨髓瘤
  • 淋巴瘤
  • 其他

第6章：重磅抗癌藥物品牌市場：按分銷管道分類的估算與趨勢分析

  • 重磅抗癌藥物品牌市場：按分銷管道分類的趨勢分析（2025 年和 2033 年）
  • 醫院藥房
  • 零售藥房
  • 其他

第7章：重磅抗癌藥物品牌市場：區域估算與趨勢分析

  • 2025 年和 2033 年重磅抗癌藥物品牌的區域市場佔有率
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 沙烏地阿拉伯
    • 南非
    • UAE
    • 科威特

第8章 競爭情勢

  • 主要市場參與企業近期趨勢及影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Bristol-Myers Squibb Company
    • Merck & Co., Inc.
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd
    • AstraZeneca
    • GSK plc
    • Novartis AG
    • Johnson & Johnson Services, Inc.
    • AbbVie Inc.
    • Amgen Inc.
簡介目錄
Product Code: GVR-2-68038-603-5

The global blockbuster oncology brands market size was valued at USD 47.2 billion in 2025 and is projected to grow from USD 51.0 billion in 2026 to USD 87.4 billion by 2033, at a CAGR of 8.0% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 38.0% in 2025. The rising prevalence of various cancer types across different age groups, coupled with ongoing advancements in oncology research, is driving market growth.

In addition, the expanding availability of innovative treatment approaches, including immunotherapies, targeted therapies, and cellular therapies, is providing patients with a broader range of therapeutic options, further supporting market expansion.

A blockbuster drug is a highly sought-after drug that generates annual sales of USD 1 billion or more for a pharmaceutical company. Regulatory bodies worldwide have accelerated approval rates for new drug therapies as first-line treatments. In addition, companies have invested heavily in research and development efforts for new drug formulations. These factors have collectively contributed to the high growth trajectory of the global market for blockbuster oncology brands.

In January 2026, according to the American Cancer Society (ACS) in its Cancer Statistics, an estimated 2.1 million new cancer cases and 0.6 million cancer deaths are expected to occur in the United States. The most common types of cancer, according to IARC, were lung and prostate cancer for men and breast cancer for women. Such a large and expanding patient population encourages pharmaceutical companies to accelerate the development of innovative oncology therapies. These new drug therapies come at a high cost to patients; however, favorable reimbursement policies are supporting the commercial success of blockbuster oncology brands and contributing to overall market growth.

Regulatory bodies worldwide, such as the Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Medicines and Healthcare Products Regulatory Agency (MHRA), and others, have fast-tracked their approval rates for the application of innovative drug therapies in cancer treatment, such as targeted immunotherapy, CAR-T cell therapy, monoclonal antibodies, and many others. Tailored treatment approaches employed by oncologists, based on genetic and molecular profiling of tumors, further enhance treatment efficacy and drive market demand.

Global Blockbuster Oncology Brands Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities across each sub-segment from 2021 to 2033. For this study, Grand View Research has segmented the global blockbuster oncology brands market report based on brands, treatment, distribution channel, and region:

  • Brands Outlook (Revenue, USD Billion, 2021 - 2033)

Opdivo

Keytruda

Perjeta

Ibrance

Tecentriq

Gazyva

Tagrisso

Darzalex

Zejula

Revlimid

Imbruvica

Others

  • Treatment Outlook (Revenue, USD Billion, 2021 - 2033)

Lung cancer

Breast cancer

Multiple myeloma

Lymphoma

Others

  • Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)

Hospital Pharmacy

Retail Pharmacy

Other

  • Regional Outlook (Revenue, USD Billion, 2021 - 2033)

North America

    • U.S.
    • Canada
    • Mexico

Europe

    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway

Asia Pacific

    • Japan
    • India
    • China
    • Australia
    • South Korea
    • Thailand

Latin America

    • Brazil
    • Argentina

Middle East and Africa

    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Blockbuster Oncology Brands Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Billion)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Blockbuster Oncology Brands Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political Landscape
      • 3.4.2.2. Economic and Social Landscape
      • 3.4.2.3. Technological Landscape
      • 3.4.2.4. Environmental Landscape
      • 3.4.2.5. Legal Landscape

Chapter 4. Blockbuster Oncology Brands Market: Brands Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Blockbuster Oncology Brands Market: Brands Movement Analysis, 2025 & 2033 (USD Billion)
  • 4.3. Opdivo
    • 4.3.1. Opdivo Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.4. Keytruda
    • 4.4.1. Keytruda Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.5. Perjeta
    • 4.5.1. Perjeta Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.6. Ibrance
    • 4.6.1. Ibrance Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.7. Tecentriq
    • 4.7.1. Tecentriq Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.8. Gazyva
    • 4.8.1. Gazyva Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.9. Tagrisso
    • 4.9.1. Tagrisso Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.10. Darzalex
    • 4.10.1. Darzalex Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.11. Zejula
    • 4.11.1. Zejula Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.12. Revlimid
    • 4.12.1. Revlimid Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.13. Imbruvica
    • 4.13.1. Imbruvica Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.14. Others
    • 4.14.1. Other Brands Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 5. Blockbuster Oncology Brands Market: Treatment Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Blockbuster Oncology Brands Market: Treatment Movement Analysis, 2025 & 2033 (USD Billion)
  • 5.3. Lung Cancer
    • 5.3.1. Lung Cancer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 5.4. Breast Cancer
    • 5.4.1. Breast Cancer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 5.5. Multiple Myeloma
    • 5.5.1. Multiple Myeloma Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 5.6. Lymphoma
    • 5.6.1. Lymphoma Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 5.7. Others
    • 5.7.1. Other Treatments Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 6. Blockbuster Oncology Brands Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Blockbuster Oncology Brands Market: Distribution Channel Movement Analysis, 2025 & 2033 (USD Billion)
  • 6.3. Hospital Pharmacy
    • 6.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.4. Retail Pharmacy
    • 6.4.1. Retail Pharmacy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.5. Other
    • 6.5.1. Other Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 7. Blockbuster Oncology Brands Market: Regional Estimates & Trend Analysis

  • 7.1. Blockbuster Oncology Brands Market Share, By Region, 2025 & 2033 (USD Billion)
  • 7.2. North America
    • 7.2.1. North America Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.3. Europe
    • 7.3.1. Europe Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.3.2. U.K.
      • 7.3.2.1. U.K. Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.3.4. France
      • 7.3.4.1. France Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.4.2. China
      • 7.4.2.1. China Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.4.4. India
      • 7.4.4.1. India Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.5. Latin America
    • 7.5.1. Latin America Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.3. South Africa
      • 7.6.3.1. South Africa Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Bristol-Myers Squibb Company
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Merck & Co., Inc.
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Pfizer Inc.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. F. Hoffmann-La Roche Ltd
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. AstraZeneca
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. GSK plc
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Novartis AG
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Johnson & Johnson Services, Inc.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. AbbVie Inc.
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Amgen Inc.
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives